XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Organization and Summary of Significant Accounting Policies - Liquidity and Going Concern - Additional Information (Details)
$ in Thousands, € in Millions
1 Months Ended 9 Months Ended
Jan. 03, 2023
USD ($)
Jan. 03, 2023
EUR (€)
Jan. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Cash and cash equivalents            
Proceeds from issuance of shares and warrants and warrant exercises, net       $ 113,800    
Net loss       (149,631) $ (82,084)  
Accumulated deficit       (618,217)   $ (468,586)
Cash and cash equivalents       $ 98,867   $ 49,898
Substantial Doubt about Going Concern, within One Year       false    
Advanz Pharma | License and Supply Agreement            
Cash and cash equivalents            
Upfront payment received $ 10,700 € 10.0 $ 10,700